UBS Group’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-2,427
| Closed | -$8K | – | 8792 |
|
|
2019
Q4 | $8K | Sell |
2,427
-8,826
| -78% | -$28.1K | ﹤0.01% | 7425 |
|
|
2019
Q3 | $34K | Buy |
11,253
+10,253
| +1,025% | +$28.8K | ﹤0.01% | 6423 |
|
|
2019
Q2 | $2K | Sell |
1,000
-1,413
| -59% | -$4.22K | ﹤0.01% | 7674 |
|
|
2019
Q1 | $9K | Sell |
2,413
-1,730,584
| -100% | -$6.48M | ﹤0.01% | 6911 |
|
|
2018
Q4 | $6.22M | Buy |
1,732,997
+1,725,874
| +24,230% | +$7.51M | ﹤0.01% | 1970 |
|
|
2018
Q3 | $41K | Buy |
7,123
+2,187
| +44% | +$12.5K | ﹤0.01% | 6313 |
|
|
2018
Q2 | $25K | Buy |
4,936
+3,936
| +394% | +$20.3K | ﹤0.01% | 6554 |
|
|
2018
Q1 | $5K | Sell |
1,000
-297
| -23% | -$1.79K | ﹤0.01% | 7273 |
|
|
2017
Q4 | $8K | Sell |
1,297
-4,670
| -78% | -$28.1K | ﹤0.01% | 7188 |
|
|
2017
Q3 | $34K | Buy |
5,967
+4,967
| +497% | +$25.7K | ﹤0.01% | 6085 |
|
|
2017
Q2 | $5K | Hold |
1,000
| – | – | ﹤0.01% | 7157 |
|
|
2017
Q1 | $5K | Sell |
1,000
-615
| -38% | -$5.92K | ﹤0.01% | 7026 |
|
|
2016
Q4 | $18K | Sell |
1,615
-1,014
| -39% | -$9.54K | ﹤0.01% | 6594 |
|
|
2016
Q3 | $25K | Buy |
2,629
+1,152
| +78% | +$9.63K | ﹤0.01% | 6116 |
|
|
2016
Q2 | $9K | Sell |
1,477
-1,834
| -55% | -$12.2K | ﹤0.01% | 6864 |
|
|
2016
Q1 | $22K | Buy |
3,311
+1,536
| +87% | +$9.9K | ﹤0.01% | 6144 |
|
|
2015
Q4 | $15K | Buy |
1,775
+333
| +23% | +$2.49K | ﹤0.01% | 7028 |
|
|
2015
Q3 | $11K | Sell |
1,442
-8,210
| -85% | -$83.7K | ﹤0.01% | 7223 |
|
|
2015
Q2 | $99K | Buy |
9,652
+6,795
| +238% | +$75.1K | ﹤0.01% | 5417 |
|
|
2015
Q1 | $26K | Buy |
+2,857
| New | +$25.6K | ﹤0.01% | 6710 |
|
UBS Group's FOMX Position: Q1 2020 in Review
UBS Group sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 2,427 shares — an estimated $8K sold.
UBS Group first reported a position in FOMX in Q1 2015 and held it in 20 quarters. The position peaked at $6.22M in Q4 2018. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- UBS Group reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 2,427 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $8K.
- UBS Group first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2015 and held it in 20 quarters.
- UBS Group's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $6.22M in Q4 2018.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.